Anti-inflammatory Food Parameters in Alzheimer’s Disease: A Narrative Review

Document Type : Review Article

Authors

1 School of Medicine, Isfahan University of Medical Sciences, Kashan, Iran

2 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Science, Kashan University of Medical Sciences, Ravand, Kashan, Iran.

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and inflammation. Recent studies suggest that dietary interventions may play a role in modulating inflammatory processes associated with AD. This narrative review aimed to explore the anti-inflammatory food parameters that may influence the pathophysiology of AD. A comprehensive literature search was conducted using databases such as PubMed, Scopus, Science Direct, Cochrane, Ovid, Google Scholar, and Web of Science. Studies focusing on the relationship between dietary components, inflammation, and AD were included utilizing the keywords of anti-inflammatory agents, anti-inflammatory foods, nutraceuticals, Alzheimer’s disease, AD, and cognitive decline. The review highlighted several food parameters with anti-inflammatory properties that may benefit AD patients. Omega-3 fatty acids found in fish and flaxseed oil were shown to reduce neuroinflammation. Antioxidantrich foods like berries and green leafy vegetables were demonstrated to mitigate oxidative stress. Additionally, polyphenols from sources such as tea and dark chocolate were found to have neuroprotective effects. In conclusion, specific anti-inflammatory foods were illustrated to provide a promising adjunctive strategy for managing AD. It seems that further researches are needed to establish definitive dietary guidelines and understand the underlying mechanisms of these food parameters in AD pathology.

Highlights

Minoo Akbarzadeh Morshedi (Google Scholar)

Keywords

References

  1. Ioannou K, Bucci M, Tzortzakakis A, et al. Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer’s disease compared to comorbid cases; proof of concept in the ADNI study. Mol Psychiatry. 2025;30:587-99. DOI: 10.1038/s41380-024-02672-9. PMID: 39179903.
  2. Zhou F, Sun Y, Xie X, et al. Blood and CSF chemokines in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Alzheimers Res Ther. 2023;15:107. DOI: 10.1186/s13195-023-01254-1. PMID: 37291639
  3. Liu S, Geng D. A systematic analysis for disease burden, risk factors, and trend projection of Alzheimer’s disease and other dementias in China and globally. PLoS One. 2025;20:e0322574. DOI: 10.1371/journal.pone.0322574. PMID: 40333703.
  4. Islam R, Choudhary HH, Zhang F, et al. Microglial TLR4-Lyn kinase is a critical regulator of neuroinflammation, Aβ phagocytosis, neuronal damage, and cell survival in Alzheimer’s disease. Sci Rep. 2025;15:11368. DOI: 10.1038/s41598-025-96456-y. PMID: 40175501.
  5. Abbas K, Mustafa M, Alam M, et al. Multi-target approach to Alzheimer’s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid-modulating mechanisms. Neurogenetics. 2025;26:39. DOI: 10.1007/s10048-025-00821-y. PMID: 40167826.
  6. Malekzadeh S, Owoyele BV, Khodabandeh Z, et al. Porphyromonas gingivalis, Neuroinflammation and Alzheimer’s. Niger J Physiol Sci. 2022;37:157-64. DOI: 10.54548/njps.v37i2.1. PMID: 38243562.
  7. Oyovwi MO, Chijiokwu EA, Ben-Azu B, Atere AD, Joseph UG, Ogbutor UG, et al. Potential Roles of Natural Antioxidants in Modulating Neurodegenerative Disease Pathways. Mol Neurobiol. 2025:1-31. DOI:10.1007/s12035-025-04874-w. PMID: 40202704.
  8. Hedayati A, Homayuon M, Mobaracky A, et al. Lithium chloride, ketogenic diet and stem cell transplantation in treatment of bipolar disorder. Int J Nutr Sci. 2024;9:80-82. DOI: 10.30476/IJNS.2024.99601.1250.
  9. Homayoon M, Mehrabani D, Edalatmanesh MA, et al. In Vitro Effect of Lithium Chloride on Adipose Tissue Derived Stem Cells Proliferation and Growth Kinetic. Iran J Med Sci. 2026;51:445-454. DOI: 10.30476/ijms.2026.108735.4372. PMID: 42370021.
  10. Tang JM, Lu Q, Lin HX, et al. C-reactive protein-mediated dementia. Psychogeriatrics. 2025;25:e70032. DOI:10.1111/psyg.70032. PMID: 40194896.
  11. Chen D, Sun Y. Current Status of Plant-Based Bioactive Compounds as Therapeutics in Alzheimer’s Diseases. J Integr Neurosci. 2025;24:23090. DOI: 10.31083/JIN23090. PMID: 39862001.
  12. Mehrabani D, Vahedi M, Eftekhari MH, et al. Food avoidance in patients with ulcerative colitis: a review. Int J Nutr Sci. 2018;2:189-95.
  13. Mafe AN, Büsselberg D. Could a Mediterranean Diet Modulate Alzheimer’s Disease Progression? The Role of Gut Microbiota and Metabolite Signatures in Neurodegeneration. Foods. 2025;14:1559. DOI: 10.3390/foods14091559. PMID: 40361641.
  14. Malekzadeh S, Edalatmanesh MA, Mehrabani D, et al. Dental Pulp Stem Cells Transplantation Improves Passive Avoidance Memory and Neuroinflammation in Trimethyltin-Induced Alzheimer’s Disease Rat Model. Galen Med J. 2021;10:e2254. DOI: 10.31661/gmj.v10i.2254.
  15. Braden-Kuhle PN, Lacy VA, Brice KN, et al. A Mediterranean-style diet protects against cognitive and behavioral deficits, adiposity, and Alzheimer's disease-related markers, compared to a macronutrient-matched typical American diet in C57BL/6J mice. J Alzheimers Dis. 2025;104:678-97. DOI:10.1177/13872877251319467. PMID: 40007076.
  16. Pansieri J, Pisa M, Yee S, et al. Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex. Ann Neurol. 2025;97:1067-73. DOI:10.1002/ana.27231. PMID: 40195794.
  17. Malekzadeh S, Edalatmanesh MA, Mehrabani D, et al. Effect of the xenograft transplantation of human dental pulp stem cells on anxiety and memory in trimethyltin induced-alzheimer disease model. J Qom Univ Med Sci. 2019;13:10-21.
  18. Han J, Zhang Z, Zhang P, Yu Q, Cheng Q, Lu Z, et al. The roles of microglia and astrocytes in neuroinflammation of Alzheimer’s disease. Front Neurosci. 2025;19:1575453. DOI: 10.3389/fnins.2025.1575453. PMID: 40400619.
  19. Malekzadeh S, Edalatmanesh MA, Mehrabani D, et al. Dental tissue-derived stem cells as a candidate for neural regeneration. Cell Ther Reg Med. 2017;1:115-22. DOI: 10.15562/ctrm.28.
  20. Ebrahimi R, Shahrokhi Nejad S, Falah Tafti M, et al. Microglial activation as a hallmark of neuroinflammation in Alzheimer’s disease. Metabolic Brain Disease. 2025;40:207. DOI: 10.1007/s11011-025-01631-9. PMID: 40381069.
  21. Tork MAB, Fotouhi S, Roozi P, et al. Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders. Mol Neurobiol. 2025;62:1840-81. DOI:10.1007/s12035-024-04359-2. PMID: 39042218.
  22. Kodi T, Sankhe R, Gopinathan A, Nandakumar K, Kishore A. New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation. J Neuroimmune Pharmacol. 2024;19:7. DOI:10.1007/s11481-024-10101-5. PMID: 38421496.
  23. Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, et al. Inflammatory process in Alzheimer's Disease. Frontiers Integr Neurosci. 2013;7:59. DOI: 10.3389/fnint.2013.00059. PMID: 23964211.
  24. Ayyubova G, Fazal N. Beneficial versus Detrimental Effects of Complement–Microglial Interactions in Alzheimer’s Disease. Brain Sci. 2024;14:434. DOI: 10.3390/brainsci14050434. PMID: 38790413.
  25. Goudarzi Z, Hoseini SE, Mehrabani D, et al. Change in blood chemistry, pro-inflammatory cytokines, and apoptotic genes following methamphetamine use in experimental rats. Periódico Tchê Química. 2020;17:1147-1159. DOI: 10.52571/ptq.v17.n36.2020.1163_periodico36_pgs_1147_1159.pdf.
  26. Yang SS, Simtchouk S, Julien G, et al. Regulation of the phagocytic activity of astrocytes by neuroimmune mediators endogenous to the central nervous system. PLoS One. 2023;18:e0289169. DOI: 10.1371/journal.pone.0289169. PMID: 37498903.
  27. Botella Lucena P, Heneka MT. Inflammatory aspects of Alzheimer’s disease. Acta Neuropathol. 2024;148:31. DOI: 10.1007/s00401-024-02790-2. PMID: 39196440.
  28. Sidoryk-Węgrzynowicz M, Adamiak K, Strużyńska L. Astrocyte–Neuron Interaction via the Glutamate–Glutamine Cycle and Its Dysfunction in Tau-Dependent Neurodegeneration. Int J Mol Sci. 2024;25:3050. DOI: 10.3390/ijms25053050. PMID: 38474295.
  29. Sarkar S, Porel P, Kosey S, et al. Diverse role of S100 calcium-binding protein B in alzheimer’s disease: pathological mechanisms and therapeutic implications. Inflammopharmacology. 2025;33:1803-1816. DOI: 10.1007/s10787-025-01697-y. PMID: 40057929.
  30. Kedia S, Simons M. Oligodendrocytes in Alzheimer’s disease pathophysiology. Nat Neurosci. 2025;28:446-456. DOI: 10.1038/s41593-025-01873-x. PMID: 39881195.
  31. Sun Y, Islam S, Michikawa M, et al. Presenilin: A multi-functional molecule in the pathogenesis of Alzheimer’s disease and other neurodegenerative diseases. Int J Mol Sci. 2024;25:1757. DOI: 10.3390/ijms25031757. PMID: 38339035.
  32. Bie B, Wu J, Foss JF, et al. Activation of mGluR1 mediates C1q-dependent microglial phagocytosis of glutamatergic synapses in Alzheimer’s rodent models. Mol Neurobiol. 2019;56:5568-85. DOI: 10.1007/s12035-019-1467-8. PMID: 30652266.
  33. Lian H, Yang L, Cole A, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron. 2015;85:101-15. DOI: 10.1016/j.neuron.2014.11.018. PMID: 25533482.
  34. Zhu XC, Wang HF, Jiang T, et al. Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts. Mol Neurobiol. 2017;54:551-62. DOI:10.1007/s12035-015-9638-8. PMID: 26742530.
  35. Ng AN, Salter EW, Georgiou J, et al. Amyloid-β1-42 oligomers enhance mGlu5R-dependent synaptic weakening via NMDAR activation and complement C5aR1 signaling. Iscience. 2023;26:108412. DOI: 10.1016/j.isci.2023.108412. PMID: 38053635.
  36. Mohamed Asik R, Suganthy N, Aarifa MA, et al. Alzheimer’s disease: A molecular view of β-amyloid induced morbific events. Biomedicines. 2021;9:1126. DOI: 10.3390/biomedicines9091126. PMID: 34572312.
  37. Ahn EH, Park JB. Molecular Mechanisms of Alzheimer’s Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy. Cells. 2025;14:89. DOI: 10.3390/cells14020089. PMID: 39851517.
  38. Kapoor M, Chinnathambi S. TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization: a specialized Tau perspective. J Neuroinflammation. 2023;20:72. DOI: 10.1186/s12974-023-02751-8. PMID: 36915196.
  39. Kimura A, Yoshikura N, Hayashi Y, et al. Cerebrospinal fluid CC motif chemokine ligand 2 correlates with brain atrophy and cognitive impairment in Alzheimer’s disease. J Alzheimers Dis. 2017;61:581-8. DOI: 10.3233/JAD-170519. PMID: 29171996.
  40. Moussa N, Dayoub N. Exploring the role of COX-2 in Alzheimer's disease: Potential therapeutic implications of COX-2 inhibitors. Saudi Pharm J. 2023;31:101729. DOI:10.1016/j.jsps.2023.101729. PMID: 37638222.
  41. Guan PP, Liang YY, Cao LL, et al. Cyclooxygenase-2 Induced the beta-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E(2) and 15-Deoxy-Delta(12,14)-prostaglandin J(2). Neurotherapeutics. 2019;16:1255-68. DOI:10.1007/s13311-019-00770-z. PMID: 31392591.
  42. Liy PM, Puzi NNA, Jose S, et al. Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells. Exp Biol Med (Maywood). 2021;246:2399-406. DOI:10.1177/1535370221997052. PMID: 33715528.
  43. Parsa F, Hoseini SE, Mehrabani D, et al. The effect of Cannabis sativa on memory, apoptotic genes and inflammatory cytokines in rat. Acad J Health Sci Med Balear. 2021;36:96-101.
  44. Zhang H, Wei W, Zhao M, et al. Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease. Int J Biol Sci. 2021;17:2181. DOI: 10.7150/ijbs.57078. PMID: 34239348.
  45. Yan H, Wang W, Cui T, et al. Advances in the Understanding of the Correlation Between Neuroinflammation and Microglia in Alzheimer’s Disease. ImmunoTargets Ther. 2024:287-304. DOI: 10.2147/ITT.S455881. PMID: 38881647.
  46. Sun Y, Koyama Y, Shimada S. Inflammation from peripheral organs to the brain: how does systemic inflammation cause neuroinflammation? Front Aging Neurosci. 2022;14:903455. DOI: 10.3389/fnagi.2022.903455. PMID: 35783147.
  47. Shamsdin SA, Mehrafshan A, Rakei SM, et al. Evaluation of VEGF, FGF and PDGF and serum levels of inflammatory cytokines in patients with glioma and meningioma in Southern Iran. Asian Pac J Cancer Prev. 2019;20:2883-90. DOI: 10.31557/APJCP.2019.20.10.2883. PMID: 31653130.
  48. Motamedifar M, Handjani F, Hadi N, et al. Seroprevalence Of Varicella Zoster Virus In Children From Shiraz, Iran. Iran J Immunol. 2006;3:43-46.
  49. Sugasini D, Park JC, McAnany JJ, et al. Improvement of retinal function in Alzheimer disease-associated retinopathy by dietary lysophosphatidylcholine-EPA/DHA. Sci Rep. 2023;13:9179. DOI:10.1038/s41598-023-36268-0. PMID: 37280266.
  50. Mohit M, Mousavinezhad H, Karami E, et al. The Effect of Different Types of Dietary Fatty Acids on Body Fat: A Review. Int J Nutr Sci. 2022;7:125-130. DOI: 10.30476/IJNS.2022.95602.1190.
  51. Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. DOI: 10.1016/j.prostaglandins.2025.106948. PMID: 39756792.
  52. Yazdani J, Dehzad MJ, Ommati MM, et al. The Effect of Banana (Musa nana Lour.) Peel Extract and Omega-3 on Biochemical and Histopathological Characteritics in Rat Model of Polycystic Ovary Syndrome. Int J Nutr Sci. 2025;10:93-103. DOI: 10.30476/ijns.2025.101331.1297.
  53. Ajith TA. A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer's Disease. Curr Clin Pharmacol. 2018;13:252-60. DOI:10.2174/1574884713666180807145648. DOI: 10.2174/1574884713666180807145648. PMID: 30084334.
  54. Hassanshahi N, Masoumi SJ. The Effect of Omega-3 Fatty Acids in Ulcerative Colitis: A

Systematic Review. Int J Nutr Sci. 2018;3:58-64.

  1. Thomas J, Garg ML, Smith DW. Dietary supplementation with resveratrol and/or docosahexaenoic acid alters hippocampal gene expression in adult C57Bl/6 mice. J Nutr Biochem. 2013;24:1735-40. DOI:10.1016/j.jnutbio.2013.03.002. PMID: 23746933.
  2. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1538-44. DOI:10.1016/j.pnpbp.2008.05.015. PMID: 18573585.
  3. Lee LK, Shahar S, Chin AV, et al. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2013;225:605-12. DOI:10.1007/s00213-012-2848-0. PMID: 22932777.
  4. Wang Y, Zhang H, Ding F, et al. N-3 polyunsaturated fatty acids attenuate amyloid-beta-induced toxicity in AD transgenic Caenorhabditis elegans via promotion of proteasomal activity and activation of PPAR-gamma. J Nutr Biochem. 2024;127:109603. DOI:10.1016/j.jnutbio.2024.109603. PMID: 38373507.
  5. Wang L, Cheng C, Yu X, et al. Conversion of α-linolenic acid into n-3 long-chain polyunsaturated fatty acids: bioavailability and dietary regulation. Cri Rev Food Sci Nutr. 2025;65:6470-6502. DOI: 10.1080/10408398.2024.2442064. PMID: 39686568.
  6. Rahimlou M, Jahromi NB, Hasanyani N, et al. Effects of Flaxseed Interventions on Circulating Inflammatory Biomarkers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2019;10:1108-19. DOI:10.1093/advances/nmz048. PMID: 31115436.
  7. Rom S, Zuluaga-Ramirez V, Reichenbach NL, et al. Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation. J Neuroinflammation. 2018;15:25. DOI: 10.1186/s12974-018-1065-0. PMID: 29373982.
  8. Ogawa T, Sawane K, Ookoshi K, et al. Supplementation with Flaxseed Oil Rich in Alpha-Linolenic Acid Improves Verbal Fluency in Healthy Older Adults. Nutrients. 2023;15:1499. DOI:10.3390/nu15061499. PMID: 36986229.
  9. Wesołowska W, Bachoń E, Doligalska M, et al. Omega-3 Fatty Acids: Key Players in Cognitive Function and Brain Health. J Educat Health Sport. 2025;77:56776. DOI: 10.12775/JEHS.2025.77.56776.
  10. Hosseini SE, Mehrabani D, Rezaei E. Effects of pomegranate juice on liver enzymes (ALT, ALP, AST) in diabetic and non-diabetic rats. J Anim Physiol Develop. 2014;24:59-64.
  11. Vicente-Zurdo D, Gómez-Mejía E, Rosales-Conrado N, León-González ME. A comprehensive analytical review of polyphenols: evaluating neuroprotection in Alzheimer’s disease. Int J Mol Sci. 2024;25:5906. DOI: 10.3390/ijms25115906. PMID: 38892094.
  12. Singh L, Wani AW, Shaifali, et al. A comprehensive review on neurotrophic receptors and their implications in brain health: Exploring the neuroprotective potential of berries. J Berry Res. 2025;15:48-64. DOI: 10.1177/1878509324130.
  13. Hou Y, Chu X, Park JH, et al. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimers Dement. 2024;20:4212-33. DOI:10.1002/alz.13847. PMID: 38753870.
  14. Krikorian R, Shidler MD, Nash TA, et al. Blueberry supplementation improves memory in older adults. J Agric Food Chem. 2010;58:3996-4000. DOI:10.1021/jf9029332.
  15. Kruszka J, Martyński J, Szewczyk-Golec K, et al. The Role of Selected Flavonoids in Modulating Neuroinflammation in Alzheimer’s Disease: Mechanisms and Therapeutic Potential. Brain Sci. 2025;15:485. DOI: 10.3390/brainsci15050485. PMID: 40426656.
  16. Hosseini SE, Rezaei E, Mehrabani D, et al. Effect of pomegranate juice on lipid profile in streptozotocin-induced diabetic adult male rats. J Exp Anim Biol. 2013;2:13-20.
  17. Wang W, Long P, He M, et al. Pomegranate polyphenol punicalagin as a nutraceutical for mitigating mild cognitive impairment: an overview of beneficial properties. Eur J Pharmacol. 2024;977:176750. DOI: 10.1016/j.ejphar.2024.176750. PMID: 38897439.
  18. Ullah A, Khan A, Ahmed S, et al. A review of pomegranate supplementation: A promising remedial avenue for Alzheimer's disease. Heliyon. 2023;9:e22483. DOI:10.1016/j.heliyon.2023.e22483. PMID: 38074891.
  19. Subash S, Essa MM, Al-Asmi A, et al. Pomegranate from Oman Alleviates the Brain Oxidative Damage in Transgenic Mouse Model of Alzheimer's disease. J Tradit Complement Med. 2014;4:232-8. DOI:10.4103/2225-4110.139107. PMID: 25379464.
  20. Rojanathammanee L, Puig KL, Combs CK. Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease. J Nutr. 2013;143:597-605. DOI:10.3945/jn.112.169516. PMID: 23468550.
  21. Ojo OA, Maduakolam-Aniobi TC, Gyebi GA, et al. Experimental and computational analyses of the anti-alzheimer and antidiabetic effects of flavonoid-rich extract of avocado seeds (Persea americana Mill.). Nutrire. 2025;50:1-27.
  22. Cheng FW, Ford NA, Wood AC, et al. Avocado consumption and markers of inflammation: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Eur J Nutr. 2023;62:2105-13. DOI:10.1007/s00394-023-03134-8. PMID: 36947255.
  23. Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res Ther. 2015;7:33. DOI: 10.1186/s13195-015-0117-2. PMID: 25802557.
  24. Marra A, Manousakis V, Koutis N, , et al. In Vitro Antioxidant, Antithrombotic and Anti-Inflammatory Activities of the Amphiphilic Bioactives Extracted from Avocado and Its By-Products. Antioxidants (Basel). 2025;14:146. DOI:10.3390/antiox14020146. PMID: 40002333.
  25. Hashemi SS, Rezaeian R, Rafati AR, et al. A review on application of herbals and their polymer composites in wound healing. Arab J Chem. 2024;17:1-15. DOI: 10.1016/j.arabjc.2024.105820.
  26. Sharma A, Kumar Y. Nature’s derivative (s) as alternative anti-Alzheimer’s disease treatments. J Alzheimers Dis Rep. 2019;3:279-97. DOI: 10.3233/ADR-190137. PMID: 31867567.
  27. Aqababa H, Mottahedzadeh R, Shahabi S, et al. The action of Ginkgo biloba on passive avoidance learning in experimental rats. Middle-East J Sci Res. 2013;16:751-755. DOI: 10.5555/20133375169.
  28. Sangeet S, Khan A. Bacopa monnieri phytochemicals as promising BACE1 inhibitors for Alzheimer's disease therapy. Sci Rep. 2025;15:13504. DOI:10.1038/s41598-025-92644-y. PMID: 40251199.
  29. Abdul Manap AS, Vijayabalan S, Madhavan P, et al. Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. Drug Target Insights. 2019;13:1177392819866412. DOI:10.1177/1177392819866412. PMID: 31391778.
  30. Dwivedi S, Nagarajan R, Hanif K, et al. Standardized Extract of Bacopa monniera Attenuates Okadaic Acid Induced Memory Dysfunction in Rats: Effect on Nrf2 Pathway. Evid Based Complement Alternat Med. 2013;2013:294501. DOI:10.1155/2013/294501.
  31. Singh M, Murthy V, Ramassamy C. Modulation of hydrogen peroxide and acrolein-induced oxidative stress, mitochondrial dysfunctions and redox regulated pathways by the Bacopa monniera extract: potential implication in Alzheimer's disease. J Alzheimers Dis. 2010;21:229-47. DOI:10.3233/JAD-2010-091729. PMID: 20421692.
  32. Rastogi M, Ojha RP, Prabu PC, et al. Prevention of age-associated neurodegeneration and promotion of healthy brain ageing in female Wistar rats by long term use of bacosides. Biogerontology. 2012;13:183-95. DOI:10.1007/s10522-011-9367-y. PMID: 22143822.
  33. Uabundit N, Wattanathorn J, Mucimapura S, et al. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol. 2010;127:26-31. DOI:10.1016/j.jep.2009.09.056. PMID: 19808086.
  34. Nowak A, Kojder K, Zielonka-Brzezicka J, et al. The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer's Disease. Front Pharmacol. 2021;12:775034. DOI:10.3389/fphar.2021.775034. PMID: 34803717.
  35. Nguyen VTT, Slotos RS, Guilherme MDS, et al. Ginkgo biloba extract EGb 761® ameliorates cognitive impairment and alleviates TNFα response in 5xFAD Alzheimer‘s disease model mice. Phytomedicine. 2025;136:156327. DOI: 10.1016/j.phymed.2024.156327. PMID: 39778487.
  36. Wan W, Zhang C, Danielsen M, et al. EGb761 improves cognitive function and regulates inflammatory responses in the APP/PS1 mouse. Exp Gerontol. 2016;81:92-100. DOI:10.1016/j.exger.2016.05.007. PMID: 27220811.
  37. Gargouri B, Carstensen J, Bhatia HS, et al. Anti-neuroinflammatory effects of Ginkgo biloba extract EGb761 in LPS-activated primary microglial cells. Phytomedicine. 2018;44:45-55. DOI: 10.1016/j.phymed.2018.04.009. PMID: 29895492.
  38. Hao F, Li A, Yu H, Liu M, Wang Y, Liu J, et al. Enhanced Neuroprotective Effects of Combination Therapy with Bone Marrow-Derived Mesenchymal Stem Cells and Ginkgo biloba Extract (EGb761) in a Rat Model of Experimental Autoimmune Encephalomyelitis. Neuroimmunomodulation. 2016;23:41-57. DOI: 10.1159/000437429. PMID: 26468875.
  39. Mikulska P, Malinowska M, Ignacyk M, et al. Ashwagandha (Withania somnifera)—current research on the health-promoting activities: a narrative review. Pharmaceutics. 2023;15:1057. DOI: 10.3390/pharmaceutics15041057. PMID: 37111543.
  40. Das R, Rauf A, Akhter S, Islam MN, Emran TB, Mitra S, et al. Role of withaferin A and its derivatives in the management of Alzheimer’s disease: Recent trends and future perspectives. Molecules. 2021;26:3696. DOI: 10.3390/molecules26123696. PMID: 34204308.
  41. Kurapati KR, Atluri VS, Samikkannu T, et al. Ashwagandha (Withania somnifera) reverses beta-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS One. 2013;8:e77624. DOI: 10.1371/journal.pone.0077624. PMID: 24147038.
  42. Pandey A, Bani S, Dutt P, et al. Multifunctional neuroprotective effect of Withanone, a compound from Withania somnifera roots in alleviating cognitive dysfunction. Cytokine. 2018;102:211-21. DOI: 10.1016/j.cyto.2017.10.019. PMID: 29108796.
  43. Dubey S, Kallubai M, Subramanyam R. Improving the inhibition of beta-amyloid aggregation by withanolide and withanoside derivatives. Int J Biol Macromol. 2021;173:56-65. DOI:10.1016/j.ijbiomac.2021.01.094. PMID: 33465364.
  44. Lerose V, Ponticelli M, Benedetto N, et al. Withania somnifera (L.) Dunal, a Potential Source of Phytochemicals for Treating Neurodegenerative Diseases: A Systematic Review. Plants (Basel). 2024;13:771. DOI:10.3390/plants13060771. PMID: 38592845.
  45. Banerjee P, Wang Y, Carnevale LN, et al. diAcCA, a Pro-Drug for Carnosic Acid That Activates the Nrf2 Transcriptional Pathway, Shows Efficacy in the 5xFAD Transgenic Mouse Model of Alzheimer’s Disease. Antioxidants. 2025;14:293. DOI: 10.3390/antiox14030293. PMID: 40227330.
  46. Habtemariam S. The therapeutic potential of rosemary (Rosmarinus officinalis) diterpenes for Alzheimer’s disease. Evid Based Complement Alternat Med. 2016;2016:2680409. DOI: 10.1155/2016/2680409. PMID: 26941822.
  47. Abbaoui Z, Merzouki M, Oualdi I, et al. Alzheimer's disease: In silico study of rosemary diterpenes activities. Curr Res Toxicol. 2024;6:100159. DOI:10.1016/j.crtox.2024.100159. PMID: 38455759.
  48. Seibel R, Schneider RH, Gottlieb MGV. Effects of Spices (Saffron, Rosemary, Cinnamon, Turmeric and Ginger) in Alzheimer's Disease. Curr Alzheimer Res. 2021;18:347-57. DOI:10.2174/1567205018666210716122034. PMID: 34279199.
  49. Mehrabani D, Farjam M, Geramizadeh B, et al. The healing effect of curcumin on burn wounds in rat. World J Plast Surg. 2015;4:29-35. PMID: 25606474.
  50. Farjam M, Mehrabani D, Abbassnia F, et al. The healing effect of curcuma longa on liver in experimental acute hepatic encephalopathy of rat. Comp Clin Pathol. 2014;23:1669-1673. DOI: 10.1007/s00580-014-1883-0.
  51. Small GW, Siddarth P, Li Z, et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. Am J Geriatr Psychiatry. 2018;26:266-77. DOI:10.1016/j.jagp.2017.10.010. PMID: 29246725.
  52. Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4:43. DOI:10.1186/alzrt146. PMID: 23107780.
  53. Ai J, Nekooeian Aa, Takhshid Ma, et al. Effect Of Aqueous Extract Of Crocus Sativus L. (Saffron) Stigma On Serum Levels Of Gonadotropins And Folliculogenesis In Adult Rats. J Appl Anim Res. 2009;35:49-52. DOI: 10.1080/09712119.2009.9706983.
  54. Rasi Marzabadi L, Fazljou SMB, Araj-Khodaei M, et al. Saffron reduces some inflammation and oxidative stress markers in donepezil-treated mild-to-moderate Alzheimer's Disease patients: A randomized double-blind placebo-control trial. J Herbal Med. 2022;34:100574. DOI:10.1016/j.hermed.2022.100574.
  55. Norouzi A, Jabraeilipour A, Doustar N, et al. Saffron’s promise: a systematic review of its role in Alzheimer's treatment. Egyptian J Neurol Psychiatry Neurosurgery. 2025;61:21. DOI:10.1186/s41983-025-00950-z.
  56. Priyadarshini S, Goyal K, Gupta S, et al. Polypharmacology and Neuroprotective Effects of Gingerol in Alzheimer’s Disease. Mol Neurobiol. 2025;62:8166-8186. DOI: 10.1007/s12035-024-04484-y. PMID: 39982688.
  57. Pan Y, Li Z, Zhao X, et al. Screening of active substances regulating Alzheimer’s disease in ginger and visualization of the effectiveness on 6-gingerol pathway targets. Foods. 2024;13:612. DOI: 10.3390/foods13040612. PMID: 38397589.
  58. Gunawardena D, Govindaraghavan S, Münch G. Anti-inflammatory properties of cinnamon polyphenols and their monomeric precursors. Polyphenols in human health and disease: Elsevier; 2014.p.409-25.
  59. Nakhaee S, Kooshki A, Hormozi A, et al. Cinnamon and cognitive function: a systematic review of preclinical and clinical studies. Nutr Neurosci. 2024;27:132-46. DOI:10.1080/1028415X.2023.2166436. PMID: 36652384.
  60. Engler MB, Engler MM, Chen CY, et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr. 2004;23:197-204. DOI:10.1080/07315724.2004.10719361. PMID: 15190043.
  61. Cimini A, Gentile R, D'Angelo B, et al. Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer's disease model by modulating BDNF signaling pathway. J Cell Biochem. 2013;114:2209-20. DOI:10.1002/jcb.24548. PMID: 23554028.
  62. Fusar-Poli L, Gabbiadini A, Ciancio A, et al. The effect of cocoa-rich products on depression, anxiety, and mood: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022;62:7905-16. DOI: 10.1080/10408398.2021.1920570. PMID: 33970709.
  63. Valverde-Salazar V, Ruiz-Gabarre D, García-Escudero V. Alzheimer’s disease and green tea: epigallocatechin-3-gallate as a modulator of inflammation and oxidative stress. Antioxidants. 2023;12:1460. DOI: 10.3390/antiox12071460. PMID: 37507998.
  64. Islam MR, Rauf A, Akter S, et al. Epigallocatechin 3-gallate-induced neuroprotection in neurodegenerative diseases: molecular mechanisms and clinical insights. Mol Cell Biochem. 2025;480:3363-83. DOI:10.1007/s11010-025-05211-4. PMID: 39832108.
  65. Gonçalves PB, Sodero ACR, Cordeiro Y. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Biomolecules. 2021;11:767. DOI: 10.3390/biom11050767. PMID: 34065606.
  66. Babaei FG, Saburi E, Forouzanfar F, et al. Effect of epigallocatechin-3-gallate (EGCG) on cognitive functioning and the expression of APP and BDNF in the hippocampus of rats with streptozotocin -induced Alzheimer-like disease. Biochem Biophys Rep. 2025;41:101930. DOI:10.1016/j.bbrep.2025.101930. PMID: 39980585.
  67. Li H, Zheng C, Wang Z, et al. Neuroprotective Effects of Catechins by Differentially Affecting the Binding of Beta-amyloid and Its Aggregates to the Target Cells. Mol Neurobiol. 2025;62:9861-9880. DOI:10.1007/s12035-025-04870-0. PMID: 40172817.
International Journal of Nutrition Sciences
Volume 11, Issue 3 - Serial Number 3
September 2026
Pages 403-416

Files

Share

How to cite

Statistics